DYSIS Medical

Executive Summary

DYSIS Medical is a UK-based medical device company that has developed a computer-aided colposcopy system designed to improve the accuracy and efficiency of cervical cancer screening. Its proprietary technology, the DYSIS Colposcope combined with DYSISmap software, objectively quantifies acetowhitening changes in cervical tissue, creating a color-coded map that helps clinicians detect lesions more reliably than traditional colposcopy. Cervical cancer remains a leading cause of cancer death in women globally, especially in low-resource settings, and DYSIS addresses a critical gap in screening by reducing inter-operator variability and improving detection rates. The company was founded in 2011 and is privately held, with offices in Edinburgh, UK. The global cervical cancer diagnostics market is large and growing, driven by increasing screening awareness and adoption of advanced technologies. DYSIS's solution offers a unique value proposition by combining a standard colposcope with advanced image analysis, requiring minimal additional training. While the company has not disclosed total funding or commercial traction, its inclusion in the BiopharmGuy database suggests active development. If DYSIS can secure regulatory approvals in key markets (FDA, CE mark) and establish distribution partnerships, it could capture significant market share. However, competition from other AI-assisted diagnostic tools and traditional colposcopy may pose challenges. Overall, DYSIS Medical is well-positioned in the digital pathology space with a clear clinical need.

Upcoming Catalysts (preview)

• 2026 Q3FDA 510(k) Clearance for DYSIS Colposcope60% success
• 2026 Q4Publication of Clinical Study Results Demonstrating Improved Detection Rates70% success
• 2027 Q1Strategic Distribution Partnership for European Market Entry50% success